









Markets
/
Stocks
/
nasdaq-lnth
/

Lantheus Holdings Inc

LNTH



View Detailed Chart

66.620USD

+3.520+5.58%

Close 12/12, 16:00（ET）Quotes delayed by 15 min

4.42BMarket Cap

27.04P/E TTM



Lantheus Holdings Inc

66.620

+3.520+5.58%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+5.58%

5 Days

+5.24%

1 Month

+22.24%

6 Months

-16.87%

Year to Date

-25.53%

1 Year

-27.52%

View Detailed Chart

TradingKey Stock Score of Lantheus Holdings Inc

Currency: USD Updated: 2025-12-12

Key Insights

Lantheus Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 1/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 80.92.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lantheus Holdings Inc's Score

Industry at a Glance

Industry Ranking

1 / 208

Overall Ranking

31 / 4592

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

80.923

Target Price

+29.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Lantheus Holdings Inc Highlights

StrengthsRisks

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 64.04% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.53B.

Overvalued

The company’s latest PE is 27.04, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 78.96M shares, decreasing 9.90% quarter-over-quarter.

Held by Private Capital

Star Investor Private Capital holds 560.66K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.29.